Istradefylline medication

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Cognitive Impairment

Trial Timeline

Jul 18, 2022 → Jun 9, 2025

NCT ID

NCT05333549

About Istradefylline medication

Istradefylline medication is a phase 2 stage product being developed by Kyowa Kirin for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05333549. Target conditions include Parkinson Disease, Cognitive Impairment.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Lemborexant + placeboEisaiApproved

✅Safinamide MesilateEisaiApproved

✅Istradefylline PillKyowa KirinApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05333549	Phase 2	Completed	Jul 18, 2022	Jun 9, 2025	Parkinson Disease

Competing Products

20 competing products in Parkinson Disease

See all competitors

Product	Company	Stage	Hype Score
exidavnemab + Placebo Comparator	BioArctic AB	Phase 2	36
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
LY4006896 + Placebo	Eli Lilly	Phase 1	36
ATH-1017 + Placebo	LeonaBio	Phase 2	17
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Approved	43
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
Equfina 50 mg	Eisai	Pre-clinical	26
Equfina	Eisai	Pre-clinical	26
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
Safinamide Mesilate	Eisai	Approved	43
E2007 + E2007 + E2007	Eisai	Phase 2	35